Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Royalty Pharma logo

Royalty Pharma Income Statement

Revenue, expenses, and profitability over time

Royalty Pharma generated $2.4B in trailing twelve-month revenue, up 0.1% year-over-year. Net income was $827.3M with a 33.9% net margin. Diluted EPS is $1.91, which declined 0.2% year-over-year. Based on the Q1 2026 filing.

Total Revenue (TTM)$2.4BOperating Income (TTM)$1.6BNet Income (TTM)$827.3MEps Diluted (TTM)$1.91
Latest FilingQ1 2026
Report Date2026-05-06
Market Cap$24.5B
P/E Ratio29.63
ROE8.39%

Earnings Per Share

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Basic earnings per share$0.47$0.55$0.07$0.67$0.50$0.67
Diluted earnings per share$0.47$0.55$0.07$0.67$0.50$0.67
Weighted-average shares, basic448.2M435.5M423.5M431.9M429.8M436.8M
Weighted-average shares, diluted594.1M578.1M562.3M559.6M564.5M556.8M

Other Income & Expense

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income from equity method investments$31.7M$6.4M$2.7M$15.9M$4M$21.8M
Interest expense$65.8M$65.3M$68.7M$79.6M$94.2M$93.7M
Interest income$9M$11.3M$8.3M$6.9M$7.1M$6.2M
Gain on retained interest in Sandisk—-$45.9M-$30.6M$18.9M—-$20.2M
Other income (expense), net—-$99.7M-$119.2M$17.1M-$32.5M-$94.8M

Operating Expenses

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
General and administrative$67.6M$110.7M$179.8M$118.7M$164.3M$159.5M
Impairment charges$0$0———$69.4M
Provision for credit losses on unfunded commitments$0$0$92.5M$766K$0-$3.7M
Research and development$500K$50.5M$300.5M$50.5M$50.5M$39.8M
Total operating expenses$232.1M$34.1M$368.9M$182.1M$233.6M$67.5M

Income Before Tax

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income before income taxes$334.4M$434.4M$90.6M$444.2M$355.9M$468.3M

Tax

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income tax expense$0$0$0$0$0$0

Net Income

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net income$208.2M$239.3M$30.2M$288.2M$214.2M$294.7M

Operating Income

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Operating income$361.5M$534.2M$209.8M$427.2M$388.4M$563M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Gain (loss) on available-for-sale debt securities$51M-$3.3M-$27.4M$52.5M$24.1M-$6.7M
Distributions of earnings from equity method investees—$13.4M———$3.7M
Interest Income, Other$9M$11.3M$8.3M$6.9M$7.1M$6.2M
Interest Paid, Excluding Capitalized Interest, Operating Activity$805K$138.8M$796K$130M$6.7M$173.5M
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation—-$941.3M-$507.8M—-$299.6M-$272.7M
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation-$505.6M$503.9M-$312M-$958.3M-$847.8M-$477.9M
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation$742.5M$596.1M$364M$702.6M$827.1M$718.2M
Other income, net (Note 6)-$2.2M-$3.1M-$1.5M-$1.6M-$8.2M-$2.2M
Payments for Repurchase of Common Stock$52.6M$708.8M$291.6M$146.5M$80.5M$50.1M
Payments to Acquire Finance Receivables$496.4M$1.1M$1.1M$961.9M$733.7M$452.4M
Proceeds from Equity Method Investment, Distribution, Return of Capital$3.2M$36.3M$63M$905K$5M$42.3M
Sale of investments$12.6M$12.6M$2.9M$2.9M$2.9M$4.3M
Provision (benefit) for other credit losses$164M-$127.1M-$203.9M$12.1M$0-$197.5M

Revenue

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Total revenue$593.6M$568.2M$578.7M$609.3M$622M$630.6M